Currently out of the existing stock ratings of Nathan Weinstein, 41 are a BUY (93.18%), 3 are a HOLD (6.82%).

Nathan Weinstein

Work Performance Price Targets & Ratings Chart

Analyst Nathan Weinstein, currently employed at AEGIS, carries an average stock price target met ratio of 25.98% that have a potential upside of 16.33% achieved within 45 days.

Nathan Weinstein’s has documented 74 price targets and ratings displayed on 18 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on EVGN, Evogene at 11-Sep-2022.

Wall Street Analyst Nathan Weinstein

Analyst best performing recommendations are on AMRN (AMARIN PLC).
The best stock recommendation documented was for AMRN (AMARIN PLC) at 10/31/2019. The price target of $460 was fulfilled within 15 days with a profit of $131.6 (40.07%) receiving and performance score of 26.72.

Average potential price target upside

ATAI ATAI Life Sciences BV CDTX Cidara Therapeutics DRIO DarioHealth Corp ENVB Enveric Biosciences KTRA Kintara Therapeutics SCYX Scynexis VNRX Volitionrx Ltd IMUX Immunic MDWD Mediwound Ltd ORMP Oramed Pharmaceuticals CMMB Chemomab Therapeutics Ltd DRC ENTX Entera Bio Ltd IINN Inspira Technologies Oxy BHN Ltd ACST Acasti Pharma AVGR Avinger EVGN Evogene KIN Kindred Biosciences AMRN Amarin PLC

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$15

$9.9 (194.12%)

$10

2 months 12 days ago
(29-Jul-2025)

0/5 (0%)

$11.53 (332.28%)

Buy

$11

$5.9 (115.69%)

$12

2 months 14 days ago
(27-Jul-2025)

0/4 (0%)

$7.67 (230.33%)

Buy

1 years 3 months 21 days ago
(20-Jun-2024)

0/1 (0%)

$26.23 (139.74%)

Buy

$9

$3.9 (76.47%)

2 years 5 months ago
(11-May-2023)

0/3 (0%)

$7.1 (373.68%)

Buy

2 years 6 months 14 days ago
(27-Mar-2023)

0/1 (0%)

$17.08 (114.48%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Nathan Weinstein?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?